The new marketing approach involved more of a focus on the building of brand equity, which meant getting consumers to prefer CAGP products even, potentially, at a higher price. The new approach stemmed from a desire to build a foundation for long-term success and a realization that CAGP was not, and probably would never be, among the lowest cost producers in the industry. Marketing managers were attempting to build the equity of the various CAGP brands through a variety of methods, including product and packaging design and advertising and promotions.

61 I want to ask something about cerebrovascular accident (CVA). Can you please tell me how we can rapidly pinpoint the exact anatomical site of the neurological deficit using physical findings in the emergency room?

62 Why do you treat dissection of the carotid artery with an anticoagulant in the acute management of stroke secondary to dissection? To me this seems paradoxical as it would increase the severity of dissection.

63 Last week, in a neurology viva, I was asked about the indications for heparinization in patients with a stroke. I want to know when I can stop heparin and what test I should use for assessing its therapeutic range.

64 Has heparin a role in the management of acute ischaemic stroke not accompanied by atrial fibrillation?

65 1. In the treatment of a stroke, does low-molecular-weight heparin (LMWH) have an advantage over heparin? 2. In an ischaemic stroke in evolution, for how long should heparin be administered?

66 Can streptokinase be used in acute cerebral infarction and, if so, what is the dose?

67 There seems now to be a consensus about starting aspirin therapy in acute ischaemic strokes as early as possible. Why has this changed from past recommendations to avoid aspirin early (during the first 48 hours) during the ischaemic stroke on the pretext that it could convert an ischaemic infarct into a haemorrhagic one, thus increasing the dangers of complications like cerebral oedema and raised intracranial pressure? If both opinions are based on clinical trials, what is the significance of the much hyped 'evidence-based medicine'?

68 I understand that a loading dose of clopidogrel 600-900 mg can be given to ischaemic stroke in evolution and can stop the evolving deficit. Would you agree?

69 Is there any rationale for giving patients with recurrent strokes a combination of aspirin and anticoagulant?

70 1. Does a dipyridamol-aspirin combination have any superiority over aspirin alone in the secondary prevention of a stroke? 2. Is an aspirin plus anticoagulant combination superior to a dipyridamol aspirin combination in the treatment of recurrent ischaemic stroke not controlled by aspirin alone?